{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-282855","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2026-06-25T20:26:17+00:00","discovered_at":"2026-06-25T20:27:00.437601+00:00","generated_at":"2026-06-25T20:27:19.198537+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Taysha Gene Therapies prices $200M public offering of 32.5M shares at $6.00/share","bullets":["Offering of 32,500,001 shares at $6.00/share and 833,333 pre-funded warrants at $5.999.","Net proceeds ~$187.4M; up to ~$215.6M if underwriters exercise 5M over-allotment option.","Underwriters: Jefferies, Goldman Sachs, Piper Sandler, Cantor; Baird as lead manager.","Company expects cash runway into second half of 2028.","Offering expected to close June 26, 2026; dilution to existing shareholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-282855","json":"https://secwatch.observer/filing/0001193125-26-282855.json","markdown":"https://secwatch.observer/filing/0001193125-26-282855.md","text":"https://secwatch.observer/filing/0001193125-26-282855.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526282855/0001193125-26-282855-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526282855/d121397d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T20:27:19.198537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}